Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stake Raised by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,365 shares of the biotechnology company’s stock after buying an additional 2,822 shares during the period. SG Americas Securities LLC’s holdings in Aldeyra Therapeutics were worth $112,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ALDX. US Bancorp DE bought a new stake in shares of Aldeyra Therapeutics during the third quarter valued at approximately $30,000. Paloma Partners Management Co bought a new stake in Aldeyra Therapeutics during the third quarter worth approximately $62,000. The Manufacturers Life Insurance Company raised its holdings in Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 2,729 shares in the last quarter. King Wealth Management Group raised its holdings in Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 2,700 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Aldeyra Therapeutics by 253.3% during the third quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 10,201 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Trading Up 1.7 %

Shares of NASDAQ:ALDX opened at $6.03 on Thursday. Aldeyra Therapeutics, Inc has a 12 month low of $2.71 and a 12 month high of $6.55. The stock’s 50 day moving average price is $5.15 and its 200 day moving average price is $5.18. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.